Adlai Nortye Raises $100 Million in Series D Financing Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures
BriefingWire.com, 7/15/2021 - NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as Adlai Nortye ), a global biopharmaceutical company focused on developing innovative oncology dr gs, today announced the completion of $100 million Series D financing round. Co-led by SDIC Fund Management and Tigermed, this round of financing is participated by Legend Star, Wuxi Biologicals Healthcare Ventures, Triwise Capital, Qingdao Mukui, Guolian Industrial Investment, Tian Ge Interactive, etc. Proceeds from the financing will be used to accelerate the development of ongoing clinical and preclinical programs, expand dr g portfolio through in-house R&D capability, in-licensi
(1)
NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as Adlai Nortye ), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. Co-led by SDIC Fund Management and Tigermed, this round of financing is participated by Legend Star, Wuxi Biologicals Healthcare Ventures, Triwise Capital, Qingdao Mukui, Guolian Industrial Investment, Tian Ge Interactive, etc. Proceeds from the financing will be used to accelerate the development of ongoing clinical and preclinical programs, expand drug portfolio through in-house R&D capability, in-licensing, mergers and acquisitions and other strategic collaborations.
Thursday, 15 July 2021, 4:05 pm
Adlai Nortye Ltd. (hereinafter referred to as Adlai
Nortye ), a global biopharmaceutical company focused on
developing innovative oncology drugs, today announced the
completion of $100 million Series D financing round. Co-led
by SDIC Fund Management and Tigermed, this round of
financing is participated by Legend Star, Wuxi Biologicals
Healthcare Ventures, Triwise Capital, Qingdao Mukui, Guolian
Industrial Investment, Tian Ge Interactive, etc. Proceeds
from the financing will be used to accelerate the
development of ongoing clinical and preclinical programs,
expand drug portfolio through in-house R&D capability,
in-licensing, mergers and acquisitions and other strategic
collaborations. We intend to develop differentiated